The influence of specific activity on the biodistribution of 18F-rhPSMA-7.3: a retrospective analysis of clinical PET data

T Langbein, A Wurzer, A Gafita… - Journal of Nuclear …, 2022 - Soc Nuclear Med
We investigated whether the time between synthesis and injection and the resulting
decrease in specific activity affects the normal-organ and tumor uptake of the PSMA ligand …

Quantitative and qualitative analysis of biodistribution and PET image quality of novel radiohybrid PSMA ligand, 18F-rhPSMA-7, in patients with prostate cancer

SW Oh, A Wurzer, E Teoh, S Oh, G Buschner, M Herz… - 2019 - Soc Nuclear Med
1557 Objectives: Prostate-specific membrane antigen (PSMA) ligands such as 68 Ga-PSMA
have an established use in positron emission tomography (PET)/computed tomography (CT) …

Biodistribution and radiation dosimetry of the novel 18F-labeled prostate-specific membrane antigen-ligand PSMA-7 for PET/CT in prostate cancer patients

M Hohberg, M Dietlein, C Kobe, F Dietlein… - 2018 - Soc Nuclear Med
88 Objectives: We investigated the whole-body distribution and the radiation dosimetry of 18
F-PSMA-7, a novel 18 F-labeled PSMA-ligand for the PET/CT imaging of prostate cancer …

Quantitative and qualitative analyses of biodistribution and PET image quality of a novel radiohybrid PSMA, 18F-rhPSMA-7, in patients with prostate cancer

SW Oh, A Wurzer, EJ Teoh, S Oh… - Journal of Nuclear …, 2020 - Soc Nuclear Med
Radiohybrid PSMA (rhPSMA) ligands, a new class of theranostic prostate-specific
membrane antigen (PSMA)–targeting agents, feature fast 18F synthesis and utility for …

PSMA PET AUC Updates: Inclusion of rh-PSMA-7.3

TA Hope, H Jadvar - Journal of Nuclear Medicine, 2024 - Soc Nuclear Med
[Posluma; BlueEarth]), the appropriate use criteria for prostatespecific membrane antigen
(PSMA) PET needs to be updated a second time (1, 2). The approval for 18F-rh-PSMA-7.3 …

Biokinetics and dosimetry of 18F‐PSMA‐1007 in patients with prostate cancer

E Hvittfeldt, M Bjöersdorff, G Brolin… - Clinical Physiology …, 2022 - Wiley Online Library
Purpose Positron emission tomography‐computed tomography (PET‐CT) using prostate‐
specific membrane antigen (PSMA) ligands is a method for imaging prostate cancer. A …

A novel 18F-labeled PSMA ligand for PET/CT imaging of prostate cancer patients: First-in-man observational study and clinical experience with 18F-JK-PSMA-7 …

F Dietlein, M Hohberg, C Kobe… - Journal of Nuclear …, 2019 - Soc Nuclear Med
In preclinical trials, the recently developed tracer 18 F-JK-PSMA-7 (2-MeO-18 F-DCFPyL)
has been demonstrated to show favorable properties regarding clinical performance and …

Intraindividual comparison of 18F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer

F Dietlein, C Kobe, M Hohberg… - Journal of nuclear …, 2020 - Soc Nuclear Med
18F-prostate-specific membrane antigen (PSMA)-1007 is excreted mainly through the liver.
We benchmarked the performance of 18F-PSMA-1007 against 3 renally excreted PSMA …

The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor …

A Afshar-Oromieh, H Hetzheim… - Journal of Nuclear …, 2015 - Soc Nuclear Med
PET imaging with the prostate-specific membrane antigen (PSMA)–targeted radioligand
68Ga-PSMA-11 is regarded as a significant step forward in the diagnosis of prostate cancer …

[HTML][HTML] F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients

FL Giesel, B Hadaschik, J Cardinale, J Radtke… - European journal of …, 2017 - Springer
Purpose The prostate-specific membrane antigen (PSMA) targeted positron-emitting-
tomography (PET) tracer 68 Ga-PSMA-11 shows great promise in the detection of prostate …